CJC-1295 with DAC is a synthetic peptide designed to stimulate your pituitary gland into releasing more growth hormone. It belongs to a class of compounds called growth hormone-releasing hormone (GHRH) analogs, meaning it mimics the natural signaling molecule your brain already uses to trigger growth hormone production. What sets CJC-1295 apart from other peptides in this category is the “DAC” modification, which keeps it active in the body for days rather than minutes.
What DAC Actually Does
DAC stands for Drug Affinity Complex. It’s a chemical modification attached to the peptide that allows it to bind to albumin, the most abundant protein in your blood. Once locked onto albumin, CJC-1295 essentially hitchhikes through your circulation, protected from the rapid breakdown that normally destroys peptides within minutes. This extends its active life to roughly 6 to 8 days after a single injection.
Without DAC, the base peptide (sometimes called Mod GRF 1-29 or CJC-1295 no DAC) is cleared from the body in about 30 minutes. That short window means it needs to be injected multiple times per day to have a sustained effect. The DAC version, by contrast, can be administered far less frequently because growth hormone levels remain elevated for days after each dose.
How It Affects Growth Hormone Levels
Clinical data show that a single injection of CJC-1295 with DAC produces dose-dependent increases in growth hormone concentrations of 2- to 10-fold, lasting 6 days or more. The downstream marker most clinicians track, IGF-1 (a hormone the liver produces in response to growth hormone), rose 1.5- to 3-fold and stayed elevated for 9 to 11 days.
With repeated dosing, the picture shifts slightly. Baseline growth hormone levels between doses climbed 7.5-fold, while overall growth hormone secretion increased by about 46% and IGF-1 levels rose approximately 45%. Notably, because the DAC version keeps the peptide circulating continuously, it raises baseline growth hormone rather than just amplifying the sharp bursts your body naturally produces during deep sleep and exercise. This is an important distinction: non-DAC versions tend to preserve the body’s normal pulsatile rhythm of growth hormone release, while the DAC version creates a more sustained elevation.
Reported Effects on Body Composition
Growth hormone drives two key processes that change body composition over time. It promotes lipolysis (the breakdown of stored fat into usable fatty acids) and supports muscle protein synthesis. People using CJC-1295, often in combination with another peptide called ipamorelin, typically report noticeable fat reduction starting around the second month, particularly in abdominal fat stores. Measurable changes in body composition generally appear within 8 to 12 weeks when combined with structured nutrition and regular exercise.
Other commonly reported effects include deeper sleep, faster recovery from workouts, improved energy, and better skin quality (likely related to increased collagen synthesis). These are consistent with what elevated growth hormone levels would be expected to produce, though individual responses vary considerably.
Side Effects
In clinical trials, CJC-1295 with DAC was generally well tolerated at lower doses. The most common side effects were injection site reactions: temporary pain, swelling, and hardness at the injection spot, sometimes with localized hives. Beyond that, reported side effects include:
- Flu-like symptoms
- Headaches
- Nausea
- Irritability and anxiety
- Hives
No serious adverse reactions were reported in early clinical studies. One death from a heart attack occurred during a 12-week Phase II trial involving 192 HIV patients, but the attending physician concluded the patient likely had pre-existing, undiagnosed coronary artery disease and that the event was unrelated to the peptide. The FDA has separately flagged potential risks including increased heart rate and systemic blood vessel dilation reactions, noting that available clinical data remain limited.
Regulatory Status
CJC-1295 is not an FDA-approved drug. It was previously available through compounding pharmacies in the United States, but its status has become more restricted. The FDA has placed CJC-1295 on a list of bulk drug substances that may present significant safety risks when compounded, citing concerns about immune reactions with certain routes of administration, difficulties with quality control during manufacturing, and limited clinical evidence.
The nominations for CJC-1295 were eventually withdrawn from the FDA’s interim policy list. In practical terms, this means access through legitimate compounding pharmacies has narrowed, and the peptide exists largely in a regulatory gray area. Products sold through online research chemical vendors are not pharmaceutical grade and carry additional risks related to purity, contamination, and accurate dosing.
How It Compares to Non-DAC Versions
The choice between CJC-1295 with DAC and without DAC comes down to convenience versus physiological mimicry. The DAC version requires less frequent injections, typically once or twice per week, and maintains consistently elevated growth hormone levels. The non-DAC version (Mod GRF 1-29) clears in about half an hour and is usually injected two to three times daily, but it produces sharper, more natural-looking growth hormone pulses that more closely resemble what a healthy pituitary does on its own.
Some practitioners prefer the non-DAC version specifically because it preserves pulsatile release patterns. Sustained elevation of growth hormone, rather than pulsatile release, could theoretically lead to different downstream effects and a greater chance of receptor desensitization over time. Both versions are frequently paired with a growth hormone-releasing peptide like ipamorelin, which amplifies the growth hormone pulse beyond what either compound produces alone.